Systematic review and meta-analysis compares long-term outcomes of vedolizumab and infliximab in biologic-naive ulcerative colitis, suggesting vedolizumab is favorable.
Key Points
This meta-analysis evaluates the long-term efficacy and safety of vedolizumab compared to infliximab in biologic-naive ulcerative colitis patients.
Systematic search across MEDLINE, Scopus, Cochrane Library, and ClinicalTrials.gov
Included biologic-naive UC patients with at least 12 months follow-up reporting outcomes of vedolizumab and infliximab
Performed random-effects meta-analyses to pool odds ratios with 95% confidence intervals.
Vedolizumab showed greater treatment persistence than infliximab at 12, 24, 36, and 48 months (no difference at 60 months)
Higher likelihood of achieving clinical and endoscopic remission at 12 months with vedolizumab
Lower incidence of serious adverse events and hospitalization rates with vedolizumab.